<PAGE>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549


                                   FORM 10-QSB

[X]     Quarterly  Report  pursuant  to  Section  13  or 15(d) of the Securities
        Exchange  Act  of  1934

        For  the  quarterly  period  ended  September  30,  2002

[ ]     Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act
        of  1934

        For  the  transition  period  from          to

Commission  File  Number  001-14297
                          ---------

                                MW Medical, Inc.
                                ----------------
        (Exact name of Small Business Issuer as specified in its charter)

Nevada                                              86-0907471
--------------------------------                    ----------
(State or other jurisdiction of                     (IRS Employer
incorporation)                                      Identification No.)

                 6929 E. Cheney, Paradise Valley, Arizona 85253
                 ----------------------------------------------
                    (Address of principal executive offices)

                                 (480) 941-3875
                                 --------------

                 Issuer's telephone number, including area code


State the number of shares outstanding of each of the issuer's classes of common
equity,  as  of  the  last  practicable  date.

          Class                              Outstanding as September 30, 2002
------------------------------------         ---------------------------------
$.001 par value Class A Common Stock                  24,517,443 shares

Transitional  Small  Business Disclosure Format (Check one): Yes [   ] No [ X  ]


<PAGE>

                         PART I - FINANCIAL INFORMATION

Item  1.      Financial  Statements.

BASIS  OF  PRESENTATION

General

The accompanying unaudited financial statements have been prepared in accordance
with  the  instructions  to  Form  10-QSB  and,  therefore,  do  not include all
information  and  footnotes  necessary  for a complete presentation of financial
position,  results  of  operations,  cash  flows,  and  stockholders' deficit in
conformity  with  generally  accepted  accounting principles.  In the opinion of
management,  all adjustments considered necessary for a fair presentation of the
results  of  operations  and  financial position have been included and all such
adjustments  are  of  a normal recurring nature.  Operating results for the nine
months  ended  September 30, 2002, are not necessarily indicative of the results
that  can  be  expected  for  the  year  ending  December  31,  2002.



                                       2

<PAGE>

                                MW Medical, Inc.

                           CONSOLIDATED BALANCE SHEETS


                                                    (Unaudited)      (Audited)
                                                    September 30,   December 31,
                                                         2002           2001
                                                    -------------  -------------
CURRENT ASSETS
  Cash                                              $     10,418   $        209
  Accounts Receivable                                                         -
  Inventory                                              300,000        300,000
  Other current assets
                                                    -------------  -------------

          Total current assets                           310,418        300,209

INVENTORY, long-term

PROPERTY AND EQUIPMENT, net of allowance                  26,897         55,928
  for depreciation of $346,625 and $317,544
OTHER RECEIVABLES, net                                                        -
                                                    -------------  -------------

                                                    $    337,315   $    356,137
                                                    =============  =============

        LIABILITIES AND STOCKHOLDERS' (DEFICIT)

CURRENT LIABILITIES
  Accounts payable                                  $    276,960   $    241,617
  Accrued expenses                                       762,880        510,867
  Note payable - related party                           716,221        615,871
                                                    -------------  -------------

          Total current liabilities                    1,756,061      1,368,355

COMMITMENTS AND CONTINGENCIES                                  -              -

STOCKHOLDERS' (DEFICIT)
  Common stock $.001 par value;
    authorized - 100,000,000 shares issued and
    outstanding, 24,517,443                               24,517         24,517
  Additional paid-in capital                          13,687,857     13,687,857
  Note receivable from former parent
  Accumulated deficit                                (15,131,120)   (14,724,592)
                                                    -------------  -------------

          Total stockholders' (deficit)               (1,418,746)    (1,012,218)
                                                    -------------  -------------

                                                    $    337,315   $    356,137
                                                    -------------  -------------


                                       3

<PAGE>

<TABLE>
<CAPTION>
                                MW Medical, Inc.

                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                At Sept. 30, 2002
                                   (Unaudited)


                                          Three months              Nine months
                                         ended Sept. 30,           ended Sept. 30,
                                  -------------------------  ---------------------------
                                        2002          2001         2002         2001
                                  -----------  --------------------------  -------------
<S>                               <C>          <C>           <C>           <C>
Sales, net                                 -   $    48,000   $         -   $    217,560
Cost of sales                              -        41,186             -        121,978
                                  -----------  ------------  ------------  -------------
                                           -         6,814             -         95,582

General and administrative
  expenses                            99,501       192,312       326,408        623,311
Depreciation and amortization          9,677        36,978        29,031        110,805
Research and development                            58,879         1,000        258,919
                                  -----------  ------------  ------------  -------------

     Total operating expenses        109,178       288,169       356,439        993,035

     Net operating loss             (109,178)     (281,355)     (356,439)      (897,453)



  Interest income                          -
Interest income (expense)            (16,498)      (19,900)      (50,089)      (866,600)
                                  -----------  ------------  ------------  -------------

                                     (16,498)      (19,900)      (50,089)      (866,600)

Loss from continuing operations
  before income taxes               (125,676)     (301,255)     (406,528)    (1,764,053)
Income tax expense                         -             -             -              -
                                  -----------  ------------  ------------  -------------

     NET LOSS                       (125,676)     (301,255)     (406,528)    (1,764,053)
                                  ===========  ============  ============  =============

Net loss per weighted average
  share                               ($0.01)       ($0.01)       ($0.02)        ($0.08)
                                  ===========  ============  ============  =============


Weighted average number of
  common shares used to compute
  net loss per weighted average
  share                           24,517,443    22,517,443    24,517,443     21,904,943
                                  ===========  ============  ============  =============


                                       4

</TABLE>





<PAGE>

                                MW Medical, Inc.

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                              At September 30, 2002
                                   (Unaudited)



                                                Nine months ended September 30
                                                        2002         2001
                                                ---------------  ------------
Cash flows from operating activities
  Net Loss                                         $  (406,528)  $(1,764,053)
  Adjustments to reconcile net loss to
   cash used in operating activities:
     Depreciation and amortization                      29,031       110,805
     Deferred Salaries                                 252,120             -
     Expenses paid in stock                                            5,500
     Interest expense                                   50,089       817,000
     Changes in assets and liabilities
       Increase in accounts receivable                                28,641
       Decrease (increase) in inventories                            272,017
       Decrease (increase) in restricted cash                -
       Decrease (increase) in prepaid expenses
         and other receivables                                        19,873
       Increase in accounts payable and accrued
         expenses                                       41,959        15,734
       Increase in deposits                                  -
       Decrease in income taxes payable                      -
                                                ---------------  ------------

         Net cash used in operating activities         (33,329)     (494,483)
                                                ---------------  ------------

Cash flows used in investing activities
  Purchase of equipment                                      -




                                       5

<PAGE>

                                MW Medical, Inc.

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                        At September 30, 2002- Continued
                                   (Unaudited)

                                                                Nine months
                                                            ended September 30
                                                             2002      2001
                                                           --------- ---------
Cash flows from financing activities
  Capital contribution from former parent                         -         -
  Proceeds from convertible debenture offering                    -         -
  Proceeds from line of credit                                    -         -
  Proceeds from loans                                        43,538   286,000
  Payments on loans                                               -         -
  Proceeds from the exercise of stock options                     -         -
  Sale of common stock                                            -   200,000
                                                           --------- ---------

       Net cash provided by financing activities             43,538   486,000
                                                           --------- ---------

       (Decrease) increase in cash and cash equivalents      10,209    (8,483)

Cash and cash equivalents at beginning of period                209     9,825
                                                           --------- ---------

Cash and cash equivalents at end of period                 $ 10,418  $  1,342
                                                           ========= =========

Supplemental information
  Cash paid for interest                                   $      -  $      -
  Cash paid for income taxes                               $      -  $  2,400


                                       6

<PAGE>

                                MW Medical, Inc.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                         September 30, 2002 (Unaudited)


NOTE  A  -  SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES

Basis  of  presentation
-----------------------

The  accompanying  consolidated  financial  statements  have  been  prepared  in
accordance  with  generally  accepted accounting principles ("GAAP") for interim
financial information and with the instructions to Form 10QSB. Accordingly, they
do  not  include  all  of  the  information  and footnotes required by generally
accepted  auditing  principles  for complete financial statements. The unaudited
consolidated  financial  statements  and  notes  should,  therefore,  be read in
conjunction with the financial statements and notes thereto in the Annual Report
on  Form  10-KSB  for  the  year  ended  December  31,  2001.  In the opinion of
management,  all  adjustments  (consisting  of normal and recurring adjustments)
considered  necessary  for a fair presentation, have been included.  The results
of  operations  for  the  nine-month  period  ended  September  30, 2002 are not
necessarily indicative of the results that may be expected for the entire fiscal
year  2002.


NOTE  B  -  REALIZATION  OF  ASSETS

The  Company  has suffered recurring losses from operations and will continue to
incur losses for the foreseeable future.  These losses, in the past, were due to
the  significant  costs incurred in connection with manufacturing, marketing and
distributing  its  microwave  products.  The  Company  operates  in  a  highly
competitive  environment  and  is  subject to all of the risks inherent in a new
business  enterprise.

In view of the matters described in the preceding paragraph, recoverability of a
major  portion  of  the recorded asset amounts shown in the accompanying balance
sheet  is  dependent  upon continued operations of the Company, which in turn is
dependent  upon  the  Company's  ability to meet its financing requirements on a
continuing  basis,  to  maintain present financing, and to succeed in its future
operations.  The financial statements do not include any adjustments relating to
the  recoverability  and classification of recorded asset amounts or amounts and
classification  of  liabilities  that  might  be necessary should the Company be
unable  to  continue  in  existence.


                                       7

<PAGE>

                                MW Medical, Inc.

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

                         September 30, 2002 (Unaudited)


NOTE  B  -  REALIZATION  OF  ASSETS  -  Continued


Management  has  taken  the following steps, which it believes are sufficient to
provide  the  Company  with the ability to continue its operations over the near
term:  The Company has reduced staffing to key personnel, specifically corporate
officers  and  technicians  necessary  to  continue  manufacturing  operations.
Additionally,  all  officers  are voluntarily participating in a salary deferral
program  until  additional  funding  is  secured.  The  Company  has stopped the
manufacturing  of all its systems until new funding can be secured. Sales of the
MW  2000  has been unsuccessful in the past year partially because we are unable
to  service machines outside the immediate geographical areas due to the lack of
funding  for technical staff. The Company is pursuing opportunities to establish
a  strategic  alliance  with an established entity or to possibly be acquired or
merged with another entity.  However, there can be no assurance that the Company
will  be  able to complete any contemplated alliance, merger or sale transaction
within  the  required  time  frame.


                                       8

<PAGE>

Item  2.     Management's  Discussion  and  Analysis  of Financial Condition and
Results  of  Operations.

On  January  22,  2002,  we  filed a Petition for relief under Chapter 11 of the
Bankruptcy  Code.  An  automatic  stay  is  now  in  place.  We  will  use  this
bankruptcy  to  protect  the business from our creditors while we reorganize and
try  to  work  out  a  plan  to pay our debts.  The Petition was filed in United
States  Bankruptcy Court, District of Arizona, In Re: MW MEDICAL, INC., a Nevada
Corporation,  Case  No.  02-0108-90-PHX-RTB,  and  In  Re:  MICROWAVE  MEDICAL
CORPORATION,  a California Corporation, Case No. 02-01298-PHX-GBN.  The location
of  the  United  States  Trustee  is 2929 N. Central Avenue, Suite 700, P.O. Box
36170,  Phoenix,  Arizona  85067-6170,  (602)  640-2100.

A  plan  of  organization was filed with the court, and amended on May 29, 2002.
On  October  23,  2002 we requested that the court approve the report, close the
estate and enter a final decree.  We are currently waiting for the court's final
approval.

Under  the  plan  of  organization,  there  are  no  assets to be distributed to
creditors  or  shareholders as the secured creditor has a lien on all assets and
is undersecured.  The primary objective of this reorganization is to allow us to
go forward as a public company free of all debt and with a reduced secured debt.
The  plan  also  provides  for  payment to unsecured creditors of more than they
would  receive  in a liquidation.  We can then seek business opportunities for a
reverse  merger  that will allow creditors and shareholders to realize value not
otherwise  available to them.  In the event of an inability to raise capital and
the loss of its assets, we will still have the capacity to seek a reverse merger
partner  but  we cannot assure investors a reverse merger partner will be found.

The  plan of organization stipulates only one secured creditor, Ms. Jan Wallace.
Ms.  Wallace's  security  consists  of  patented and the proprietary technology,
ongoing  product  approvals, inventory and goodwill.  Sales of the patented
product  have  not proved profitable despite investment of significant monies in
marketing efforts.  The inventory has little value beyond scrap or salvage value
except  through  the  sale  as  retail product to physicians.  Under the plan of
organization, Ms. Wallace's secured claim shall be evidenced by a new promissory
note  issued  to  Ms.  Wallace  secured  by  the  same  property.

The  largest  group  of  unsecured  creditors  consists of management and former
management  personnel  who  are  owed  salary  and  expenses.  Under the plan of
reorganization, this group of creditors' claims are being satisfied by receiving
equity in other "to be formed" companies that will have shares authorized by the
bankruptcy court.  Additionally, MW Medical's Equity Security Holders' Interests
will maintain their ownership in MW Medical in addition to receiving a small pro
rata  equity  interest  in  these  "to  be  formed"  companies.

Other  creditor's  claims  filed  during  the  bankruptcy  proceedings have been
satisfied from either our nominal cash funds available or with MW Medical shares
to  be  issued.

In the year prior to the Petition, sales had been slow.  Our small revenues have
been greatly outpaced by our operating expenses, and we are now insolvent.  With
the  economic  downturn,  our  unproven  ability  to  generate  revenues and the
economic  fallout  from the events of September 11, 2001, we have been unable to
raise additional capital.  Our secured creditor determined that the


                                       9

<PAGE>

value  of the collateral and the growing unsecured debt made it unlikely that we
could raise additional capital. Without any further loans available, and with no
prospect of raising additional capital in the face of our current balance sheet,
we were unable to continue in business without the aid of Chapter 11 protection.
Even  with the protection afforded by the bankruptcy petition, we cannot provide
investors  with  any  assurance  we  will  emerge  from  bankruptcy  as a viable
business.

Assets

Total  assets  decreased  to  $ 337,315 on September 30, 2002 from $356,137 from
December  31,  2001,  a  decrease  of  $18,822 or 5.3%.  The net change resulted

primarily  from  a  decrease  in  the  valuation  of  our  equipment.

Liabilities  And  Stockholders'  Equity

Our liabilities increased by $387,706, or 28% to $ 1,756,061 as of September 30,
2002.  The increase in liabilities was caused by unpaid salary and notes payable
-  related  party.  All  cost  involved  in the filing of the bankruptcy and the
continued  operations  of  the Company is still being funded by Ms. Wallace, our
president  and  chief  executive  officer.  These amounts are reflected in notes
payable  - related party.  The officers of the company have elected to defer all
of  their  salaries.  Stockholders'  equity decreased to a deficit of $1,418,746
from  $1,012,218  as of December 31, 2001.  The decrease in stockholders' equity
resulted  from  the  continued  net  losses  from  operations.


Results  of  Operations

Due  to  the  lack of funding and the filing of Chapter 11, Bankruptcy code, the
operations  of  the Company have consisted of planning for the reorganization of
the  Company

Net  operating  loss  for the three months ended September 30, 2002 was $109,178
compared  to  $281,355 on September 30, 2001.  This decrease in the net loss was
caused  by  our  scaling back of operations, including a reduction in employees,
closing  of  certain  clinical  sites, and no work in  research and development.

General  and  administrative  expenses  for the three months ended September 30,
2002  were  $99,501  compared  to  $192,312  for  the  same period in 2001. This
reflects  a  decrease  of  $92,811  or  48%.  This decrease was primarily due to
significant  reductions  in  staff  and  all  operating  expenses.

Research  and  development expenses were $0 for the three months ended September
30, 2002 compared to $58,879 for the same period in 2001.  The decrease reflects
the cessation of all clinical sites and research into new microwave applications
for  our  proprietary  technologies.

Depreciation  and amortization expenses for the three months ended September 30,
2002  were  $9,677 compared to $36,978 for the same period in 2001. In 2001, the
Company  wrote  down the value of its inventory.  We also wrote off the value of
all  machines  used  in  the  clinical  sites  for  research  and  development.


                                      10

<PAGE>


Liquidity  and  Capital  Resources

With the exception of new loans advanced by Ms. Wallace, the Company has no cash
resources  to  sustain operations.  While limited funds have been generated from
revenues,  it  is  unlikely cash generated from operations will be sufficient to
continue  operations.

Since  November  2000, we have relied upon Ms. Wallace to providing funding.  We
have  not  yet  identified  new  sources  for  financing and we are currently in
default  on  our  notes  to  Ms.  Wallace.

As of September 30, 2002, the Company had $10,418 in cash. The majority of these
funds  have  been  allocated  to  the  Debtor  Settlement.

We  used  cash  of  $33,329  in  our operating activities during the nine months
ending  September  30, 2002 compared to $494,483 for the same period in 2001. In
2002,  we  were  primarily  involved  in  procedures  for  the bankruptcy and in
researching the possiblity of an acquistion or a merger with another entity. The
Company  did  not  have  any  funds  for  operations.



                                      11

<PAGE>

Forward-Looking  Statements

Many  statements made in this report are forward-looking statements that are not
based  on  historical  facts.  Because  these forward-looking statements involve
risks  and  uncertainties,  there  are important factors that could cause actual
results  to  differ  materially  from  those  expressed  or  implied  by  these
forward-looking  statements.  The forward-looking statements made in this report
relate  only  to  events  as  of  the  date  on  which  the statements are made.


ITEM  3.     CONTROLS  AND  PROCEDURES.

As  required  by  Rule  13a-15  under  the  Securities Exchange Act of 1934 (the
"Exchange Act"), we carried out an evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures within the 90 days prior
to  the  filing  date of this report.  This evaluation was carried out under the
supervision  and  with the participation of our Chief Executive Officer, Ms. Jan
Wallace and Chief Financial Officer, Ms. Grace Sim.  Based upon that evaluation,
our  Chief  Executive  Officer  and  Chief  Financial Officer concluded that our
disclosure  controls  and procedures are effective in timely alerting management
to  material  information  relating to us that is required to be included in our
periodic  SEC  filings.  There  have been no significant changes in our internal
controls  or  in other factors that could significantly affect internal controls
subsequent  to  the  date  we  carried  out  our  evaluation.

Disclosure  controls  and  procedures are controls and other procedures that are
designed  to  ensure  that  information  required to be disclosed in our reports
filed or submitted under the Exchange Act is recorded, processed, summarized and
reported,  within  the  time  periods  specified  in the Securities and Exchange
Commission's  rules  and  forms.  Disclosure  controls  and  procedures include,
without  limitation, controls and procedures designed to ensure that information
required  to  be  disclosed  in  our  reports  filed  under  the Exchange Act is
accumulated  and  communicated  to  management,  including  our  Chief Executive
Officer  and  Chief  Financial  Officer,  to  allow  timely  decisions regarding
required  disclosure.


                                      12


<PAGE>

PART  II  -  OTHER  INFORMATION


Item  1.          Legal  Proceedings:

On  January  22,  2002,  we  filed a petition for relief under Chapter 11 of the
United  States  Bankruptcy  Code.  The  petition  was filed in the United States
Bankruptcy Court, District of Arizona, under Case Number 02-01090-PHX-RTB for MW
Medical  Inc.  and Case Number 02-01298-PHX-GBN for Microwave Medical Corp.  See
"Management's  Discussion  and  Analysis  of  Financial Condition and Results of
Operations"  for  more  discussion  regarding  this  proceeding.

Other  than  the  above  discussed  legal proceedings, we are not a party to any
material  litigation  and  to  our  knowledge, no such proceedings are currently
threatened.


Item  2.     Changes  in  Securities  and  Use  of  Proceeds:

None

Item  3.     Defaults  Upon  Senior  Securities:

None

Item  4.     Submission  of  Matters  to  a  Vote  of  Security  Holders:

None

Item  5.     Other  Information:

The  Company  filed  a  definitive  14A  proxy statement with the Securities and
Exchange  Commission  on November 8, 2002, and mailed same to shareholders on or
about  the  same  date,  announcing  an annual shareholder meeting scheduled for
December  2,  2002.  The  purpose  of the meeting will be to elect directors and
approve a reverse split of the stock on a basis of one share for every 25 shares
presently outstanding.  Shares outstanding on the record date of October 9, 2002
were  24,550,070.  Outstanding  shares  after  the  split  will be approximately
980,700.  Management  believes that this capital restructuring will maximize our
business  opportunities going forward by making the Company more attractive as a
target  for  a  merger  or  reverse  acquisition.

Item  6.    Exhibits  and  Reports  on  Form  8-K:

(a)     Exhibits
        None

(b)     Reports  on  Form  8-K
        None


                                      13


<PAGE>

                                   SIGNATURES

In  accordance  with  the  requirements  of the Exchange Act, the registrant has
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                      MW Medical, Inc.


DATED:    November 19, 2002           /s/Jan Wallace
                                     ____________________________________
                                     Jan Wallace, Chief Executive Officer



                                      14


<PAGE>

                                 CERTIFICATIONS

I,  Jan Wallace, Chief Executive Officer of MW Medical, Inc. (the "Registrant"),
certify  that;

(1)  I  have  reviewed  this quarterly report on Form10-QSB of MW Medical, Inc.;
(2)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of a material fact or omit to state a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;
(3)  Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  Registrant  as  of,  and for, the periods presented in this
     quarterly  report;
(4)  The  Registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules  13a-14  and  15d-14) for the Registrant and have:
     a)   designed  such  disclosure  controls  and  procedures  to  ensure that
          material  information  relating  to  the  Registrant,  including  its
          consolidated  subsidiaries, is made known to us by others within those
          entities,  particularly  during  the  period  in  which this quarterly
          report  is  being  prepared;
     b)   evaluated  the  effectiveness  of the Registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this  quarterly  report  (the  "Evaluation  Date");  and
     c)   presented  in  this  quarterly  report  our  conclusions  about  the
          effectiveness  of  the disclosure controls and procedures based on our
          evaluation  as  of  the  Evaluation  Date;
(5)  The  Registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the Registrant's auditors and the audit
     committee  of  Registrant's  board  of directors (or persons performing the
     equivalent  functions):
     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which  could  adversely  affect  the Registrant's ability to
          record,  process,  summarize  and  report  financial  data  and  have
          identified  for  the  Registrant's auditors any material weaknesses in
          internal  controls;  and
     b)   any  fraud, whether or not material, that involves management or other
          employees  who  have  a  significant role in the Registrant's internal
          controls;  and
(6)  The  Registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  facts  that  could  significantly  affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date:   November 19, 2002          /s/ Jan Wallace
                                   ___________________________________
                                   Jan Wallace
                                   Chief Executive Officer


                                      15

<PAGE>

                                 CERTIFICATIONS

I,  Grace  Sim,  Chief Financial Officer of MW Medical, Inc. (the "Registrant"),
certify  that;

(1)  I  have  reviewed  this quarterly report on Form10-QSB of MW Medical, Inc.;
(2)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of a material fact or omit to state a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;
(3)  Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  Registrant  as  of,  and for, the periods presented in this
     quarterly  report;
(4)  The  Registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules  13a-14  and  15d-14) for the Registrant and have:
     a)   designed  such  disclosure  controls  and  procedures  to  ensure that
          material  information  relating  to  the  Registrant,  including  its
          consolidated  subsidiaries, is made known to us by others within those
          entities,  particularly  during  the  period  in  which this quarterly
          report  is  being  prepared;
     b)   evaluated  the  effectiveness  of the Registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this  quarterly  report  (the  "Evaluation  Date");  and
     c)   presented  in  this  quarterly  report  our  conclusions  about  the
          effectiveness  of  the disclosure controls and procedures based on our
          evaluation  as  of  the  Evaluation  Date;
(5)  The  Registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the Registrant's auditors and the audit
     committee  of  Registrant's  board  of directors (or persons performing the
     equivalent  functions):
     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which  could  adversely  affect  the Registrant's ability to
          record,  process,  summarize  and  report  financial  data  and  have
          identified  for  the  Registrant's auditors any material weaknesses in
          internal  controls;  and
     b)   any  fraud, whether or not material, that involves management or other
          employees  who  have  a  significant role in the Registrant's internal
          controls;  and
(6)  The  Registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  facts  that  could  significantly  affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date:   November 19, 2002          /s/ Grace Sim
                                   ___________________________________
                                   Grace Sim
                                   Chief Financial Officer


                                      16